650E2-2B12, CMCC #10121 (IVI 10083) (ATCC® HB-10812)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte; somatic cell hybri  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte; somatic cell hybri
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Age adult
Strain BALB/c
Tumorigenic Yes
Effects
Yes, BALB/c and (C57BL/6 X BALB/c)F1 mice
Complete Growth Medium Modified MA plus 10% fetal bovine serum.
Complete Growth Medium
Depositor's culture medium: Modified MA plus 10% fetal bovine serum.
Culture Conditions
Temperature: 37.0°C
Isotype IgG1
Name of Depositor Cetus Corp.
U.S. Patent Number
References

Ring DB, et al. Monoclonal anti-human breast cancer antibodies. US Patent 5,629,197 dated May 13 1997

Ring DB. Antigen-binding sites of antibody molecules specific for cancer antigens. US Patent 6,054,561 dated Apr 25 2000

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Ring DB, et al. Monoclonal anti-human breast cancer antibodies. US Patent 5,629,197 dated May 13 1997

Ring DB. Antigen-binding sites of antibody molecules specific for cancer antigens. US Patent 6,054,561 dated Apr 25 2000